Brookfield selected iCapital to develop the technology behind The Alts Allocator, citing the firm’s experience creating ...
Detailed price information for Raymond James Financial (RJF-N) from The Globe and Mail including charting and trades.
Concurrent with the RECLAIM trial in AUD, Altimmune continues to enroll patients in the RESTORE Phase 2 trial evaluating pemvidutide in alcohol-associated liver disease (ALD).
Aldebaran Resources (TSXV: ALDE; US-OTC: ADBRF) says a preliminary economic assessment (PEA) for its Altar copper-gold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback